{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:50:51Z","timestamp":1777614651309,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jpba.2021.114096","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T03:27:53Z","timestamp":1619148473000},"page":"114096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Understanding of cabotegravir degradation through isolation and characterization of key degradation products and kinetic studies"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9452-5021","authenticated-orcid":false,"given":"Lidija","family":"Kova\u010d","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"\u010crnugelj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Ro\u0161kar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Trdan Lu\u0161in","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6689-3353","authenticated-orcid":false,"given":"Zdenko","family":"\u010casar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2021.114096_bib0005","first-page":"705","article-title":"Cabotegravir","volume":"40","author":"Han","year":"2015","journal-title":"Drugs Future"},{"key":"10.1016\/j.jpba.2021.114096_bib0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/COH.0000000000000597","article-title":"Long-acting injectable cabotegravir for the prevention of HIV infection","volume":"15","author":"Clement","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jpba.2021.114096_bib0015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/14656566.2020.1843635","article-title":"An evaluation of cabotegravir for HIV treatment and prevention","volume":"22","author":"Canetti","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jpba.2021.114096_bib0020","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1358\/dof.2012.37.10.1855759","article-title":"Dolutegravir: HIV integrase inhibitor treatment of HIV infection","volume":"37","author":"Wainberg","year":"2012","journal-title":"Drugs Future"},{"key":"10.1016\/j.jpba.2021.114096_bib0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/COH.0000000000000168","article-title":"Formulation and pharmacology of long-acting cabotegravir","volume":"10","author":"Trezza","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.jpba.2021.114096_bib0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/13543776.2020.1717470","article-title":"A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor","volume":"30","author":"Kova\u010d","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.jpba.2021.114096_bib0035","series-title":"ViiV Healthcare Announces First Global Regulatory Approval of CABENUVA; the First Complete, Long-acting, Regimen for the Treatment of HIV.","author":"Healthcare","year":"2020"},{"key":"10.1016\/j.jpba.2021.114096_bib0040","series-title":"FDA Approves First Extended-release, Injectable Drug Regimen for Adults Living With HIV.","author":"Food","year":"2021"},{"key":"10.1016\/j.jpba.2021.114096_bib0045","series-title":"European Medicines Agency, Vocabria","year":"2020"},{"key":"10.1016\/j.jpba.2021.114096_bib0050","series-title":"U.S. National Library of Medicine, ClinicalTrials.gov","year":"2021"},{"key":"10.1016\/j.jpba.2021.114096_bib0055","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.trac.2017.10.021","article-title":"Critical review on establishment and availability of impurity and degradation product reference standards, challenges faced by the users, recent developments, and trends","volume":"101","author":"Kumar Singh","year":"2018","journal-title":"TrAC, Trends Anal. Chem"},{"key":"10.1016\/j.jpba.2021.114096_bib0060","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jpba.2019.06.022","article-title":"Identification, isolation and characterization of dolutegravir forced degradation products and their cytotoxicity potential","volume":"174","author":"Saida","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2021.114096_bib0065","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11094-019-02007-x","article-title":"Study of dolutegravir degradation and spectroscopic identification of products by LCMS, 1H and 13C NMR techniques","volume":"53","author":"Kumar","year":"2019","journal-title":"Pharm. Chem. J."},{"key":"10.1016\/j.jpba.2021.114096_bib0070","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1039\/C5NJ00698H","article-title":"Quality by design based development of a selective stability-indicating UPLC method of dolutegravir and characterization of its degradation products by UPLC-QTOF-MS\/MS","volume":"39","author":"Kalariya","year":"2015","journal-title":"New J. Chem."},{"key":"10.1016\/j.jpba.2021.114096_bib0075","series-title":"International Conference on Harmonisation Guideline on Stability Testing of New Drug Substances and Products Q1A(R2)","year":"2003"},{"key":"10.1016\/j.jpba.2021.114096_bib0080","series-title":"International Conference on Harmonisation Guideline on Stability Testing: Photostability Testing of New Drug Substances and Products Q.1B.","year":"1996"},{"key":"10.1016\/j.jpba.2021.114096_bib0085","series-title":"Handbook of Modern Pharmaceutical Analysis","first-page":"85","article-title":"Degradation and impurity analysis for pharmaceutical drug candidates","author":"Alsante","year":"2001"},{"key":"10.1016\/j.jpba.2021.114096_bib0090","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/jo01299a014","article-title":"General-acid-catalyzed ring opening of oxazolidines. Hydrolysis of 2-[4-(dimethylamino)styryl]-N-phenyl-1,3-oxazolidine","volume":"45","author":"Fife","year":"1980","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.jpba.2021.114096_bib0095","doi-asserted-by":"crossref","first-page":"9559","DOI":"10.1016\/S0040-4020(02)01287-5","article-title":"Stereoelectronic control of oxazolidine ring-opening: structural and chemical evidences","volume":"58","author":"Selambarom","year":"2002","journal-title":"Tetrahedron"},{"key":"10.1016\/j.jpba.2021.114096_bib0100","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1002\/jps.22108","article-title":"Stability studies of oxazolidine-based compounds using 1H NMR spectroscopy","volume":"99","author":"Moloney","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2021.114096_bib0105","series-title":"Drug Stability for Pharmaceutical Scientists","author":"Loftsson","year":"2014"},{"key":"10.1016\/j.jpba.2021.114096_bib0110","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.xphs.2018.10.059","article-title":"Enrichment of relevant oxidative degradation products in pharmaceuticals with targeted chemoselective oxidation","volume":"108","author":"Nanda","year":"2019","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2021.114096_bib0115","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1021\/jo01062a004","article-title":"Reactions of hydrogen peroxide. VII. Alakli-catalyzed epoxidation and oxidation using a nitrile as co-reactant","volume":"26","author":"Payne","year":"1961","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.jpba.2021.114096_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/PDT-120002237","article-title":"Stabilization of pharmaceuticals to oxidative degradation","volume":"7","author":"Waterman","year":"2002","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.jpba.2021.114096_bib0125","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1039\/b202620c","article-title":"Formation of singlet molecular oxygen by the Radziszewski reaction between acetonitrile and hydrogen peroxide in the absence and presence of ketones","volume":"2002","author":"Brauer","year":"2002","journal-title":"J. Chem. Soc. Perkin Trans. 2"},{"key":"10.1016\/j.jpba.2021.114096_bib0130","series-title":"Applications of Hydrogen Peroxide and Derivatives","first-page":"37","article-title":"Activation of hydrogen peroxide using inorganic and organic species","author":"Jones","year":"1999"},{"key":"10.1016\/j.jpba.2021.114096_bib0135","series-title":"Ullmann\u2019s Encyclopedia of Industrial Chemistry","article-title":"Peroxy compounds, organic","author":"Uhl","year":"2018"},{"key":"10.1016\/j.jpba.2021.114096_bib0140","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/cssc.202002364","article-title":"Biobased aldehydes from fatty epoxides through thermal cleavage of \u03b2\u2010hydroxy hydroperoxides","volume":"14","author":"De Dios Miguel","year":"2021","journal-title":"ChemSusChem"},{"key":"10.1016\/j.jpba.2021.114096_bib0145","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1021\/jo00403a029","article-title":"Rates and scope of the oxidative carbon-carbon cleavage of epoxides by alkaline hydrogen peroxide","volume":"43","author":"Ogata","year":"1978","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.jpba.2021.114096_bib0150","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1021\/jo00795a007","article-title":"Base-catalyzed fragmentation of 2-tert-butylperoxy-2-methyl-1-propanol","volume":"37","author":"Richardson","year":"1972","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.jpba.2021.114096_bib0155","doi-asserted-by":"crossref","first-page":"6292","DOI":"10.1021\/ja00515a023","article-title":"Acyclic mechanism in the cleavage of benzils with alkaline hydrogen peroxide","volume":"101","author":"Sawaki","year":"1979","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jpba.2021.114096_bib0160","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1021\/ja00353a030","article-title":"Mechanism of carbon-carbon cleavage of cyclic 1,2-diketones with alkaline hydrogen peroxide. The acyclic mechanism and its application to the basic autoxidation of pyrogallol","volume":"105","author":"Sawaki","year":"1983","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jpba.2021.114096_bib0165","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1016\/j.tetlet.2010.09.028","article-title":"Oxidation of benzoins to benzils using sodium hydride","volume":"51","author":"Joo","year":"2010","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.jpba.2021.114096_bib0170","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.tetlet.2012.10.127","article-title":"In situ generation of hydroperoxide by oxidation of benzhydrols to benzophenones using sodium hydride under oxygen atmosphere: use for the oxidative cleavage of cyclic 1,2-diketones to dicarboxylic acids","volume":"54","author":"Kang","year":"2013","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.jpba.2021.114096_bib0175","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1021\/cr960079j","article-title":"The chemistry of vicinal polycarbonyl compounds","volume":"100","author":"Mordecai","year":"2000","journal-title":"Chem. Rev."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521002077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708521002077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:12:07Z","timestamp":1760001127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708521002077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":35,"alternative-id":["S0731708521002077"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114096","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding of cabotegravir degradation through isolation and characterization of key degradation products and kinetic studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2021.114096","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114096"}}